Details:
Tocilizumab Biosimilar is a recombinant humanized monoclonal antibody targeting IL-6R, which specifically binds to sIL-6R and mIL-6R and inhibits signaling mediated by sIL-6R or mIL-6R. It is approved for the treatment of RA, sJIA, and CRS.
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: DRL_TC
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
ALZUMAb-L (Itolizumab), an anti-CD6 monoclonal antibody targets CD6-ALCAM pathway, commercialized in India since 2013 for plaque psoriasis, and emergency use authorization in COVID-19. Equillium has expanded its EQUALISE study in Systemic Lupus Erythematosus in India.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab-L
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Equillium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2021